Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q1 2022 · 10-Q
Revenue$120.37M$120.37M+16.8% vs Q1 2021 Net Income$24.25M$24.25M+381.1% vs Q1 2021 EPS Diluted$0.47$0.47+370.0% vs Q1 2021 Gross Profit$55,826,000+24.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flow$50,765,000+122.4% Free Cash Flowderived$44,626,000+193.5% Margins · derivedGross margin46.4%+2.8 pt vs Q1 2021
Operating margin18.0%+8.0 pt vs Q1 2021
Net margin20.1%+15.3 pt vs Q1 2021
ended Mar 31, 2022 · filed May 10, 2022 · 40 d after period end